Approval of Bristol-Myers Squibb?s (BMY) Yervoy [ipilimumab] for melanoma in March 2011 marked the second victory for the field of active immunotherapy in oncology within a year, with the first being the U.S. Food and Drug Administration [FDA] approval of Dendreon Corporation?s (DNDN) Provenge [sipuleucel-T] for metastatic castrate-resistant prostate cancer [CRPC] in April 2010. Ipilimumab and sipuleucel-T were the first two active immunotherapies for cancer to demonstrate improved survival in randomized Phase 3 trials and both were published in the prestigious New England Journal of Medicine within one month of each other.
The similarities don?t end there, as both ipilimumab and sipuleucel-T have reignited enthusiasm for the field of active immunotherapy. Accordingly, the purpose of this article is to highlight some of the other parallels between these two innovative agents.
Both Studied in Prostate Cancer
While ipilimumab was recently approved for the treatment of melanoma, the product has also been
Complete Story »
VARIAN SEMICONDUCTOR EQUIPMENT ASSOCIATES UNITED ONLINE UNISYS TRIQUINT SEMICONDUCTOR TRIMBLE NAVIGATION LIMITED
No comments:
Post a Comment